ArticleFrontiers in neurology
Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rimegepant, an oral calcitonin gene-related peptide receptor antagonist approved for both acute and preventive migraine treatment, demonstrates efficacy in clinical trials, but real-world evidence remains limited. This study examined the association between rimegepant use and changes in migraine frequency and patient-reported outcomes in a real-world clinical setting. Methods: This retrospective cohort study conducted at The first affiliated hospital of Chongqing Medical University, analyzed medical records of 40 adults (aged 18-65 years) with chronic ( Results: Forty participants (mean age 41.12 ± 10.86 years; 80% women) were included, comprising 21 with chronic migraine and 19 with episodic migraine. All five outcome measures improved significantly from baseline to Month 3 (all Conclusions: In this retrospective cohort of patients with prior inadequate response to preventive therapy, Every-other-day rimegepant was associated with meaningful reductions in migraine frequency and headache-related disability over 3 months in both chronic and episodic migraine patients. These preliminary findings are encouraging but require confirmation in prospective controlled studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.